Alcohol Fact Sheets. World Health Organization; 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/alcohol. (last accessed Aug 8, 2024).

Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513–23.

Article  PubMed  PubMed Central  Google Scholar 

Alcohol Abuse Statistics. National Center for Drug Abuse Statistics. Available at: https://drugabusestatistics.org/alcohol-abuse-statistics/ (last accessed Aug 8, 2024).

Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, et al. Evidence-based pharmacotherapies for alcohol use disorder: clinical pearls. Mayo Clin Proc. 2020;95(9):1964–77.

Article  CAS  PubMed  Google Scholar 

McPheeters M, O’Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for alcohol use disorder. JAMA. 2023;330(17):1653.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Latif W, Lambrinos KJ, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.

Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-like peptide 1 receptor agonists and heart failure. Circulation. 2020;142(12):1205–18.

Article  CAS  PubMed  Google Scholar 

Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS One. 2013;8(4): e61965.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21(2):422–37.

Article  PubMed  Google Scholar 

Herman RJ, Hayes MR, Audrain-Mcgovern J, Ashare RL, Schmidt HD. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology. 2023;240(6):1373–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urbanik LA, Acharya NK, Grigson PS. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats. Brain Res Bull. 2022;189:155–62.

Article  CAS  PubMed  Google Scholar 

Douton JE, Horvath N, Mills-Huffnagle S, Nyland JE, Hajnal A, Grigson PS. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addiction Biol. 2022. https://doi.org/10.1111/adb.13117.

Article  Google Scholar 

Douton JE, Acharya NK, Stoltzfus B, Sun D, Grigson PS, Nyland JE. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behav Pharmacol. 2022;33(5):364–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99(4):2115–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology. 2019;236(2):603–11.

Article  CAS  PubMed  Google Scholar 

Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013;38(8):1259–70.

Article  CAS  PubMed  Google Scholar 

Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L, Spigelman I. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci. 2020. https://doi.org/10.3389/fnins.2020.599646.

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Wang Z, Wang W, Wang Z, Xing Y, Hölscher C. Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice. Neurochem Res. 2024;49(4):1061–75.

Article  CAS  PubMed  Google Scholar 

Vallöf D, Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology. 2019;149:124–32.

Article  PubMed  Google Scholar 

Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.

Article  PubMed  PubMed Central  Google Scholar 

Zorrilla EP, Koob GF. Impulsivity derived from the dark side: neurocircuits that contribute to negative urgency. Front Behav Neurosci. 2019;13.

Neupane SP. Neuroimmune interface in the comorbidity between alcohol use disorder and major depression. Front Immunol. 2016. https://doi.org/10.3389/fimmu.2016.00655.

Article  PubMed  PubMed Central  Google Scholar 

Pascual M, Baliño P, Aragón CMG, Guerri C. Cytokines and chemokines as biomarkers of ethanol-induced neuroinflammation and anxiety-related behavior: role of TLR4 and TLR2. Neuropharmacology. 2015;89:352–9.

Article  CAS  PubMed  Google Scholar 

De Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology. 1992;107(2–3):352–8.

Article  PubMed  Google Scholar 

Yin S, Liao C, Wu C, Li T, Chen L, Lai C, et al. Human stomach alcohol and aldehyde dehydrogenases: comparison of expression pattern and activities in alimentary tract. Gastroenterology. 1997;112(3):766–75.

Article  CAS  PubMed  Google Scholar 

Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jorgensen MB, Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol. 2022;131(5):372–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klausen MK, Jensen ME, Moller M, Le Dous N, Jensen AO, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. https://doi.org/10.1172/jci.insight.159863.

Article  PubMed  PubMed Central  Google Scholar 

Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagström H. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut. 2024. https://doi.org/10.1136/gutjnl-2023-330962.

Article  PubMed  Google Scholar 

Yen F-S, Hou M-C, Wei JC-C, Shih Y-H, Hwu C-M, Hsu C-C. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med. 2024. https://doi.org/10.1186/s12916-023-03228-4.

Article  PubMed  PubMed Central  Google Scholar 

<i>Standards of Medical Care in Diabetes—2021</i> Abridged for Primary Care Providers. Clinical Diabetes. 2021;39(1):14-43.

Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517–33.

Article  CAS  PubMed  Google Scholar 

Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016;21(4):409–19.

Article  CAS  PubMed  Google Scholar 

Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–94.

Article  CAS  PubMed  Google Scholar 

VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457, U.S. Department of Veterans Affairs. (2008). Retrieved [date], from